Ketamine as a new treatment for depression: A review of its efficacy and adverse effects

Australian and New Zealand Journal of Psychiatry

Volumn 47, Issue 8, 2013, Pages 710-727

  Katalinic, Natalie ^a   Lai, Rosalyn ^a   Somogyi, Andrew ^b   Mitchell, Philip B ^a,c   Glue, Paul ^d   Loo, Colleen K ^a,c,e,f  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c BLACK DOG INSTITUTE   (Australia)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e ST GEORGE HOSPITAL   (Australia)

^f WESLEY HOSPITAL   (Australia)

Author keywords

Adverse effects; antidepressive agents; depressive disorder; ketamine; treatment outcome

Indexed keywords

ESKETAMINE; FENTANYL; KETAMINE; PROPOFOL; RILUZOLE;

ANTIDEPRESSANT ACTIVITY; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; BOLUS INJECTION; COGNITIVE DEFECT; CONFUSION; DEPRESSION; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; HEART RATE; HUMAN; LIVER TOXICITY; MAINTENANCE DRUG DOSE; META ANALYSIS (TOPIC); NAUSEA; NEGATIVE SYNDROME; OPTIMAL DRUG DOSE; PERCEPTION DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW;

ADVERSE EFFECTS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; KETAMINE; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DEPRESSIVE DISORDER; HUMANS; KETAMINE; TREATMENT OUTCOME;

EID: 84884218593     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867413486842     Document Type: Review

References (100)

1. aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry. 2010 ; 67: 139-145
2. Abdallah CG, Fasula M, Kelmendi B, et al. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. Journal of ECT. 2012 ; 28:: 157-161
3. Abel KM, Allin MP, Hemsley DR, et al. Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology. 2003 ; 44: 729-737
4. Adler CM, Goldberg TE, Malhotra AK, et al. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biological Psychiatry. 1998 ; 43: 811-816
5. Anand A, Charney DS, Oren DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists. Archives of General Psychiatry. 2000 ; 57: 270-276
6. Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011 ; 475: 91-95
7. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry. 2000 ; 47: 351-354
8. Chu PS, Ma WK, Wong SC, et al. The destruction of the lower urinary tract by ketamine abuse: a new syndrome?. British Journal of Urology International. 2008 ; 102: 1616-1622
9. Collier BB. Long-term dangers of ketamine anaesthesia. British Journal of Anaesthesia. 1981 ; 53:: 552
10. Cottrell A, Gillatt D. Ketamine-associated urinary track pathology: the tip of the iceberg for urologists?. British Journal of Medical and Surgical Urology. 2008 ; 1:: 136-138
11. Coull JT, Morgan H, Cambridge VC, et al. Ketamine perturbs perception of the flow of time in healthy volunteers. Psychopharmacology (Berlin). 2011 ; 218: 543-556
12. Curran HV, Morgan C. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction. 2000 ; 95: 575-590
13. Cusin C, Hilton GQ, Nierenberg AA, et al. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. American Journal of Psychiatry. 2012 ; 169: 868-869
14. Denk MC, Rewerts C, Holsboer F, et al. Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation. American Journal of Psychiatry. 2011 ; 168:: 751-752
15. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry. 2010 ; 67: 793-802
16. Domino EF, Chodoff P, Corssen G. Pharmacologic effects of Ci-581, a new dissociative anesthetic, in man. Clinical Pharmacology and Therapeutics. 1965 ; 6: 279-291
17. Dundee JW, Fee JP, Moore J, et al. Changes in serum enzyme levels following ketamine infusions. Anaesthesia. 1980 ; 35: 12-16
18. Ebert B, Mikkelsen S, Thorkildsen C, et al. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. European Journal of Pharmacology. 1997 ; 333: 99-104
19. Ebert B, Thorkildsen C, Andersen S, et al. Opioid analgesics as noncompetitive N-methyl-d-aspartate (NMDA) antagonists. Biochemical Pharmacology. 1998 ; 56: 553-559
20. Ghoneim MM, Hinrichs JV, Mewaldt SP, et al. Ketamine: behavioral effects of subanesthetic doses. Journal of Clinical Psychopharmacology. 1985 ; 5: 70-77
21. Glue P, Gulati A, Le Nedelec M, et al. Dose- and exposure-response to ketamine in depression. Biological Psychiatry. 2011 ; 70: e9 - e10
22. Goforth HW, Holsinger T. Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. Journal of ECT. 2007 ; 23: 23-25
23. Gregoire MC, MacLellan DL, Finley GA. A pediatric case of ketamine-associated cystitis. Urology. 2008 ; 71: 1232-1233
24. Harborne GC, Watson FL, Healy DT, et al. The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers. Journal of Psychopharmacology. 1996 ; 10:: 134-140
25. Hetem LA, Danion JM, Diemunsch P, et al. Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology (Berlin). 2000 ; 152: 283-288
26. Hirota K, Lambert DG. Ketamine: its mechanism(s) of action and unusual clinical uses. British Journal of Anaesthesia. 1996 ; 77: 441-444
27. Ho CC, Pezhman H, Praveen S, et al. Ketamine-associated ulcerative cystitis: a case report and literature review. Malaysian Journal of Medical Science. 2010 ; 17: 61-65
28. Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesthesia and Analgesia. 2003 ; 97: 1730-1739
29. Honey GD, Honey RA, Sharar SR, et al. Impairment of specific episodic memory processes by sub-psychotic doses of ketamine: the effects of levels of processing at encoding and of the subsequent retrieval task. Psychopharmacology (Berlin). 2005 ; 181: 445-457
30. Honey GD, O'Loughlin C, Turner DC, et al. The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: implications for pharmacological modelling of core symptoms of schizophrenia. Neuropsychopharmacology. 2006 ; 31: 413-423
31. Honey RA, Turner DC, Honey GD, et al. Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory. Neuropsychopharmacology. 2003 ; 28: 2037-2044
32. Ibrahim L, Diazgranados N, Franco-Chaves J, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs. add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology. 2012 ; 37: 1526-1533
33. Ibrahim L, Diazgranados N, Luckenbaugh DA, et al. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2011 ; 35: 1155-1159
34. Irwin SA, Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. Journal of Palliative Medicine. 2010 ; 13: 903-908
35. Kiefer RT, Rohr P, Ploppa A, et al. Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study. Pain Medicine. 2008 ; 9: 1173-1201
36. Knox JW, Bovill JG, Clarke RS, et al. Clinical studies of induction agents. XXXVI: Ketamine. British Journal of Anaesthesia. 1970 ; 42: 875-885
37. Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesthesia and Analgesia. 1998 ; 87: 1186-1193
38. Kollmar R, Markovic K, Thurauf N, et al. Ketamine followed by memantine for the treatment of major depression. Australian and New Zealand Journal of Psychiatry. 2008 ; 42: 170
39. Krystal JH, Bennett A, Abi-Saab D, et al. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biological Psychiatry. 2000 ; 47: 137-143
40. Krystal JH, Karper LP, Bennett A, et al. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berlin). 1998 ; 135: 213-229
41. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry. 1994 ; 51: 199-214
42. Kudoh A, Takahira Y, Katagai H, et al. Small-dose ketamine improves the postoperative state of depressed patients. Anesthesia and Analgesia. 2002 ; 95: 114-118
43. Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. International Journal of Neuropsychopharmacology. 2011 ; 14:: 1127-1131
44. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010 ; 329: 959-964
45. Liebrenz M, Borgeat A, Leisinger R, et al. Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Medical Weekly. 2007 ; 137: 234-236
46. Liebrenz M, Stohler R, Borgeat A. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World Journal of Biological Psychiatry. 2009 ; 10:: 640-643
47. Lofwall MR, Griffiths RR, Mintzer MZ. Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults. Experimental and Clinical Psychopharmacology. 2006 ; 14: 439-449
48. Loo CK, Katalinic N, Garfield JB, et al. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. Journal of Affective Disorders. 2012 ; 142: 233-240
49. Machado-Vieira R, Yuan P, Brutsche N, et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-d-aspartate antagonist. Journal of Clinical Psychiatry. 2009 ; 70: 1662-1666
50. MacLennan FM. Ketamine tolerance and hallucinations in children. Anaesthesia. 1982 ; 37: 1214-1215
51. Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 1996 ; 14: 301-307
52. Mason K, Cottrell AM, Corrigan AG, et al. Ketamine-associated lower urinary tract destruction: a new radiological challenge. Clinical Radiology. 2010 ; 65: 795-800
53. Mathew SJ, Murrough JW, aan het Rot M, et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. International Journal of Neuropsychopharmacology. 2010 ; 13: 71-82
54. Messer M, Haller IV, Larson P, et al. The use of a series of ketamine infusions in two patients with treatment-resistant depression. Journal of Neuropsychiatry and Clinical Neurosciences. 2010 ; 22:: 442-444
55. MIMS (2010) MIMS Online. Available at: http://proxy36.use.hcn.com.au/ Search/FullPI.aspx?ModuleName=Product%20Info&searchKeyword= ketamine&PreviousPage=∼/Search/QuickSearch.aspx&SearchType=&ID= 19050001-2.
56. Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berlin). 2006 ; 188: 408-424
57. Morgan CJ, Curran HV. Ketamine use: a review. Addiction. 2012 ; 107: 27-38
58. Morgan CJ, Mofeez A, Brandner B, et al. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology. 2004a ; 29: 208-218
59. Morgan CJ, Mofeez A, Brandner B, et al. Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose-response study. Psychopharmacology (Berlin). 2004b ; 172: 298-308
60. Murrough JW, Perez AM, Mathew SJ, et al. A case of sustained remission following an acute course of ketamine in treatment-resistant depression. Journal of Clinical Psychiatry. 2011 ; 72: 414-415
61. Newcomer JW, Farber NB, Jevtovic-Todorovic V, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 1999 ; 20: 106-118
62. Noppers IM, Niesters M, Aarts LP, et al. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases. Pain. 2011 ; 152: 2173-2178
63. Okamoto N, Nakai T, Sakamoto K, et al. Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia. Journal of ECT. 2010 ; 26: 223-227
64. Ostroff R, Gonzales M, Sanacora G. Antidepressant effect of ketamine during ECT. American Journal of Psychiatry. 2005 ; 162: 1385-1386
65. Oxley JD, Cottrell AM, Adams S, et al. Ketamine cystitis as a mimic of carcinoma in situ. Histopathology. 2009 ; 55: 705-708
66. Parwani A, Weiler MA, Blaxton TA, et al. The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers. Psychopharmacology (Berlin). 2005 ; 183: 265-274
67. Paslakis G, Gilles M, Meyer-Lindenberg A, et al. Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry. 2010 ; 43: 33-35
68. Passie T, Karst M, Wiese B, et al. Effects of different subanesthetic doses of (S)-ketamine on neuropsychology, psychopathology, and state of consciousness in man. Neuropsychobiology. 2005 ; 51: 226-233
69. Paul R, Schaaff N, Padberg F, et al. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World Journal of Biological Psychiatry. 2009 ; 10: 241-244
70. Peltoniemi MA, Saari TI, Hagelberg NM, et al. Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Clinical Pharmacology and Therapeutics. 2011 ; 90: 296-302
71. Perry EB, Cramer JA, Cho HS, et al. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berlin). 2007 ; 192: 253-260
72. Persson J. Wherefore ketamine?. Current Opinion in Anaesthesiology. 2010 ; 23: 455-460
73. Pfenninger EG, Durieux ME, Himmelseher S. Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers. Anesthesiology. 2002 ; 96: 357-366
74. Phelps LE, Brutsche N, Moral JR, et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-d-aspartate antagonist. Biological Psychiatry. 2009 ; 65: 181-184
75. Pittenger C, Coric V, Banasr M, et al. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs. 2008 ; 22: 761-786
76. Price RB, Nock MK, Charney DS, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biological Psychiatry. 2009 ; 66: 522-526
77. Quibell R, Prommer EE, Mihalyo M, et al. Ketamine*. Journal of Pain and Symptom Management. 2011 ; 41: 640-649
78. Rowland LM, Astur RS, Jung RE, et al. Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology. 2005 ; 30: 633-639
79. Salvadore G, Cornwell BR, Colon-Rosario V, et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biological Psychiatry. 2009 ; 65: 289-295
80. Salvadore G, Cornwell BR, Sambataro F, et al. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology. 2010 ; 35: 1415-1422
81. Salvadore G, van der Veen JW, Zhang Y, et al. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. International Journal of Neuropsychopharmacology. 2011 ; 15: 1063-1072
82. Shahani R, Streutker C, Dickson B, et al. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology. 2007 ; 69: 810-812
83. Sigtermans MJ, van Hilten JJ, Bauer MC, et al. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain. 2009 ; 145: 304-311
84. Stefanczyk-Sapieha L, Oneschuk D, Demas M. Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer. Journal of Palliative Medicine. 2008 ; 11: 1268-1271
85. Storr TM, Quibell R. Can ketamine prescribed for pain cause damage to the urinary tract?. Palliative Medicine. 2009 ; 23: 670-672
86. Thakurta RG, Das R, Bhattacharya AK, et al. Rapid response with ketamine on suicidal cognition in resistant depression. Indian Journal of Psychological Medicine. 2012a ; 34: 170-175
87. Thakurta RG, Ray P, Kanji D, et al. Rapid antidepressant response with ketamine: is it the solution to resistant depression?. Indian Journal of Psychological Medicine. 2012b ; 34: 56-60
88. Tsai TH, Cha TL, Lin CM, et al. Ketamine-associated bladder dysfunction. International Journal of Urology. 2009 ; 16: 826-829
89. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003 ; 361: 799-808
90. Umbricht D, Schmid L, Koller R, et al. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Archives of General Psychiatry. 2000 ; 57: 1139-1147
91. Valentine GW, Mason GF, Gomez R, et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Research. 2011 ; 191: 122-127
92. Wang X, Chen Y, Zhou X, et al. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. Journal of ECT. 2012 ; 28: 128-132
93. Warden D, Rush AJ, Trivedi MH, et al. The STAR*D Project results: a comprehensive review of findings. Current Psychiatry Reports. 2007 ; 9: 449-459
94. World Health Organization (2012) Mental Health - Depression. Available at: www.who.int/mental-health/management/depression/en/.
95. Yanagihara Y, Kariya S, Ohtani M, et al. Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. Drug Metabolism and Disposition. 2001 ; 29: 887-890
96. Yanagihara Y, Ohtani M, Kariya S, et al. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharmaceutics and Drug Disposition. 2003 ; 24: 37-43
97. Zanicotti CG, Perez D, Glue P Acute and maintenance IM ketamine for a depressed patient with terminal cancer. Cairns, Australia: International Psychogeriatric Association ; 2012a :
98. Zanicotti CG, Perez D, Glue P. Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. Journal of Palliative Medicine. 2012b ; 15: 400-403
99. Zarate CA, Brutsche NE, Ibrahim L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biological Psychiatry. 2012 ; 71: 939-946
100. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry. 2006 ; 63: 856-864